English
Inhibitor antibody production against FVIII is currently the most severe complication in the treatment of hemophilia A. This production impairs the efficiency and safety of FVIII replacement therapy, the standard of care to control bleeding episodes. Inhibitor development concerns approximately 30% of hemophilia A patients and remains the major challenging issue as it degrades radically quality of life and predisposes patients to an increased risk of morbidity and mortality. The mainstay treatment relies in Immune Tolerance Induction approaches that give partial results and are not recommended in subpopulation of patients with high inhibitor titer, for whom bypassing agents are the only alternative solution. _x000D_ ERYTECH Pharma‘s innovative approach is based on the entrapment of the allergen (protein or peptide) in erythrocytes that are specifically processed to induce immune tolerization. This technology has already given promising preclinical results, demonstrating specific antibody reduction with different immunogenic proteins. TOL_HEMA project brings together complementary expertise from ERYTECH and “Hemostasis, Inflammation & Sepsis” unit managed by Pr. Négrier, the National Center of Hemophilia. _x000D_ This project will demonstrate, in a hemophilia A animal model, the capability of FVIII-loaded erythrocytes to specifically inhibit the production of anti-FVIII antibodies, inducing tolerance to further FVIII injections. _x000D_
